ERBB2 and neoplasm: A high drug-to-antibody ratio (8:1) increases the amount of payload delivered to HER2-expressing cells, while its high transmembrane permeability potentiates the bystander cytotoxic effect on proximal tumor cells, regardless of their HER2 expression status.